The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis

Burton Combes, Rodney Smith Markin, Donald E. Wheeler, Raphael Rubin, A. Brian West, A. Scott Mills, Edwin H. Eigenbrodt, Willis C. Maddrey, Santiago J. Munoz, Guadalupe Garcia-Tsao, Gregory E. Bonner, James L. Boyer, Velimir A. Luketic, Mitchell L. Shiffman, Marion G. Peters, Heather M. White, Rowen K Zetterman, Robert L. Carithers

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The frequency with which florid duct lesions are seen in needle-biopsy specimens of the liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year randomized, double-blind, placebo- controlled trial of ursodeoxycholic acid (UDCA) versus placebo. Paired biopsy specimens obtained at entry and after 2 years on medication were reviewed blindly and mostly simultaneously by a panel of 5 hepatopathologists who, earlier, had characterized the florid duct lesion, which has been well described in the pathology literature. Florid duct lesions at entry were identified in approximately 36%. Patients with earlier disease showed florid duct lesions much more frequently than those with more advanced disease. The prevalence of florid duct lesions in 60 patients receiving placebo medication fell from 38.3% to 21.7%, P = .025, over the period of 2 years. The prevalence of florid duct lesions also decreased in the 55 patients receiving UDCA, from 32.7% to 18.2%, P = .046. The prevalences of these lesions in the placebo and UDCA patients at entry and at 2 years were not significantly different from each other. The findings suggest that UDCA does not prevent ongoing bile duct destruction in patients with PBC. Instead, they support the impression that UDCA exerts its beneficial effects by protecting against the consequences of bile duct destruction.

Original languageEnglish (US)
Pages (from-to)602-605
Number of pages4
JournalHepatology
Volume30
Issue number3
DOIs
StatePublished - Sep 7 1999

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Placebos
Bile Ducts
Needle Biopsy
Pathology
Biopsy
Liver

ASJC Scopus subject areas

  • Hepatology

Cite this

Combes, B., Markin, R. S., Wheeler, D. E., Rubin, R., West, A. B., Mills, A. S., ... Carithers, R. L. (1999). The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology, 30(3), 602-605. https://doi.org/10.1002/hep.510300315

The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. / Combes, Burton; Markin, Rodney Smith; Wheeler, Donald E.; Rubin, Raphael; West, A. Brian; Mills, A. Scott; Eigenbrodt, Edwin H.; Maddrey, Willis C.; Munoz, Santiago J.; Garcia-Tsao, Guadalupe; Bonner, Gregory E.; Boyer, James L.; Luketic, Velimir A.; Shiffman, Mitchell L.; Peters, Marion G.; White, Heather M.; Zetterman, Rowen K; Carithers, Robert L.

In: Hepatology, Vol. 30, No. 3, 07.09.1999, p. 602-605.

Research output: Contribution to journalArticle

Combes, B, Markin, RS, Wheeler, DE, Rubin, R, West, AB, Mills, AS, Eigenbrodt, EH, Maddrey, WC, Munoz, SJ, Garcia-Tsao, G, Bonner, GE, Boyer, JL, Luketic, VA, Shiffman, ML, Peters, MG, White, HM, Zetterman, RK & Carithers, RL 1999, 'The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis', Hepatology, vol. 30, no. 3, pp. 602-605. https://doi.org/10.1002/hep.510300315
Combes, Burton ; Markin, Rodney Smith ; Wheeler, Donald E. ; Rubin, Raphael ; West, A. Brian ; Mills, A. Scott ; Eigenbrodt, Edwin H. ; Maddrey, Willis C. ; Munoz, Santiago J. ; Garcia-Tsao, Guadalupe ; Bonner, Gregory E. ; Boyer, James L. ; Luketic, Velimir A. ; Shiffman, Mitchell L. ; Peters, Marion G. ; White, Heather M. ; Zetterman, Rowen K ; Carithers, Robert L. / The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. In: Hepatology. 1999 ; Vol. 30, No. 3. pp. 602-605.
@article{3a1561e37a3f491fbf60b9c860893c25,
title = "The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis",
abstract = "The frequency with which florid duct lesions are seen in needle-biopsy specimens of the liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year randomized, double-blind, placebo- controlled trial of ursodeoxycholic acid (UDCA) versus placebo. Paired biopsy specimens obtained at entry and after 2 years on medication were reviewed blindly and mostly simultaneously by a panel of 5 hepatopathologists who, earlier, had characterized the florid duct lesion, which has been well described in the pathology literature. Florid duct lesions at entry were identified in approximately 36{\%}. Patients with earlier disease showed florid duct lesions much more frequently than those with more advanced disease. The prevalence of florid duct lesions in 60 patients receiving placebo medication fell from 38.3{\%} to 21.7{\%}, P = .025, over the period of 2 years. The prevalence of florid duct lesions also decreased in the 55 patients receiving UDCA, from 32.7{\%} to 18.2{\%}, P = .046. The prevalences of these lesions in the placebo and UDCA patients at entry and at 2 years were not significantly different from each other. The findings suggest that UDCA does not prevent ongoing bile duct destruction in patients with PBC. Instead, they support the impression that UDCA exerts its beneficial effects by protecting against the consequences of bile duct destruction.",
author = "Burton Combes and Markin, {Rodney Smith} and Wheeler, {Donald E.} and Raphael Rubin and West, {A. Brian} and Mills, {A. Scott} and Eigenbrodt, {Edwin H.} and Maddrey, {Willis C.} and Munoz, {Santiago J.} and Guadalupe Garcia-Tsao and Bonner, {Gregory E.} and Boyer, {James L.} and Luketic, {Velimir A.} and Shiffman, {Mitchell L.} and Peters, {Marion G.} and White, {Heather M.} and Zetterman, {Rowen K} and Carithers, {Robert L.}",
year = "1999",
month = "9",
day = "7",
doi = "10.1002/hep.510300315",
language = "English (US)",
volume = "30",
pages = "602--605",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis

AU - Combes, Burton

AU - Markin, Rodney Smith

AU - Wheeler, Donald E.

AU - Rubin, Raphael

AU - West, A. Brian

AU - Mills, A. Scott

AU - Eigenbrodt, Edwin H.

AU - Maddrey, Willis C.

AU - Munoz, Santiago J.

AU - Garcia-Tsao, Guadalupe

AU - Bonner, Gregory E.

AU - Boyer, James L.

AU - Luketic, Velimir A.

AU - Shiffman, Mitchell L.

AU - Peters, Marion G.

AU - White, Heather M.

AU - Zetterman, Rowen K

AU - Carithers, Robert L.

PY - 1999/9/7

Y1 - 1999/9/7

N2 - The frequency with which florid duct lesions are seen in needle-biopsy specimens of the liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year randomized, double-blind, placebo- controlled trial of ursodeoxycholic acid (UDCA) versus placebo. Paired biopsy specimens obtained at entry and after 2 years on medication were reviewed blindly and mostly simultaneously by a panel of 5 hepatopathologists who, earlier, had characterized the florid duct lesion, which has been well described in the pathology literature. Florid duct lesions at entry were identified in approximately 36%. Patients with earlier disease showed florid duct lesions much more frequently than those with more advanced disease. The prevalence of florid duct lesions in 60 patients receiving placebo medication fell from 38.3% to 21.7%, P = .025, over the period of 2 years. The prevalence of florid duct lesions also decreased in the 55 patients receiving UDCA, from 32.7% to 18.2%, P = .046. The prevalences of these lesions in the placebo and UDCA patients at entry and at 2 years were not significantly different from each other. The findings suggest that UDCA does not prevent ongoing bile duct destruction in patients with PBC. Instead, they support the impression that UDCA exerts its beneficial effects by protecting against the consequences of bile duct destruction.

AB - The frequency with which florid duct lesions are seen in needle-biopsy specimens of the liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year randomized, double-blind, placebo- controlled trial of ursodeoxycholic acid (UDCA) versus placebo. Paired biopsy specimens obtained at entry and after 2 years on medication were reviewed blindly and mostly simultaneously by a panel of 5 hepatopathologists who, earlier, had characterized the florid duct lesion, which has been well described in the pathology literature. Florid duct lesions at entry were identified in approximately 36%. Patients with earlier disease showed florid duct lesions much more frequently than those with more advanced disease. The prevalence of florid duct lesions in 60 patients receiving placebo medication fell from 38.3% to 21.7%, P = .025, over the period of 2 years. The prevalence of florid duct lesions also decreased in the 55 patients receiving UDCA, from 32.7% to 18.2%, P = .046. The prevalences of these lesions in the placebo and UDCA patients at entry and at 2 years were not significantly different from each other. The findings suggest that UDCA does not prevent ongoing bile duct destruction in patients with PBC. Instead, they support the impression that UDCA exerts its beneficial effects by protecting against the consequences of bile duct destruction.

UR - http://www.scopus.com/inward/record.url?scp=0032869338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032869338&partnerID=8YFLogxK

U2 - 10.1002/hep.510300315

DO - 10.1002/hep.510300315

M3 - Article

C2 - 10462363

AN - SCOPUS:0032869338

VL - 30

SP - 602

EP - 605

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -